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ABSTRACT
Background. Polypharmacy (PP) and potentially inappropriate
medications (PIM) are highly prevalent in older adults with
cancer. This study systematically reviews the associations of
PP and/or PIM with outcomes and, through a meta-analysis,
obtains estimates of postoperative outcomes associated with
PP in this population.
Materials and Methods. We searched PubMed, Embase,
Web of Science, and Cochrane Register of Clinical Trials
using standardized terms for concepts of PP, PIM, and cancer. Eligible studies included cohort studies, cross-sectional
studies, meta-analyses, and clinical trials which examined
outcomes associated with PP and/or PIM and included older
adults with cancer. A random effects model included studies
in which deﬁnitions of PP were consistent to examine the
association of PP with postoperative complications.
Results. Forty-seven articles met the inclusion criteria.
PP was deﬁned as ﬁve or more medications in 57% of the

studies. Commonly examined outcomes included chemotherapy toxicities, postoperative complications, functional
decline, hospitalization, and overall survival. PP was associated with chemotherapy toxicities (4/9 studies), falls (3/3
studies), functional decline (3/3 studies), and overall survival (2/11 studies). A meta-analysis of four studies indicated an association between PP (≥5 medications) and
postoperative complications (overall odds ratio, 1.3; 95%
conﬁdence interval [1.3–2.8]). PIM was associated with
adverse outcomes in 3 of 11 studies.
Conclusion. PP is associated with postoperative complications, chemotherapy toxicities, and physical and functional
decline. Only three studies showed an association between
PIM and outcomes. However, because of inconsistent deﬁnitions, heterogeneous populations, and variable study designs,
these associations should be further investigated in prospective studies. The Oncologist 2020;25:e94–e108

Implications for Practice: Polypharmacy and potentially inappropriate medications (PIM) are prevalent in older adults with
cancer. This systematic review summarizes the associations of polypharmacy and PIM with health outcomes in older patients
with cancer. Polypharmacy and PIM have been associated with postoperative complications, frailty, falls, medication nonadherence, chemotherapy toxicity, and mortality. These ﬁndings emphasize the prognostic importance of careful medication
review and identiﬁcation of PIM by oncology teams. They also underscore the need to develop and test interventions to
address polypharmacy and PIM in older patients with cancer, with the goal of improving outcomes in these patients.
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INTRODUCTION
In the U.S., more than half of new cancer cases and about 70%
of cancer deaths occur in adults aged 65 years or older [1]. Compared with younger cohorts, older adults are more likely to have
comorbid conditions for which medications are prescribed [2].
Older adults with cancer also have a higher rate of frailty and
geriatric syndromes compared with those without cancer [3]. For
patients receiving cancer treatment, chemotherapy and supportive care regimens often involve the prescription of multiple medications. Because of these factors, older adults with cancer are at
high risk of polypharmacy (PP), deﬁned as the simultaneous use
of multiple medications. In community-dwelling populations
of older adults without cancer, PP has been associated with
increased falls [4], hospitalization [5], and mortality [6].
There is a wide variability in the deﬁnition of PP in the existing
literature [7]. In one study of community-dwelling older adults with
cancer, 84% were on ﬁve or more medications and 43% were on
10 or more medications [8]. The use of ﬁve or more medications is
the most commonly used deﬁnition of PP in the literature, whereas
the use of 10 or more medications is commonly referred to as
“extreme PP” or “hyperpolypharmacy.” Multiple cutoffs are used in
the literature, and studies vary as to how medications are counted
(i.e., whether only scheduled prescription medications are
included, or whether supplements, over-the-counter medications, and as-needed medications are counted as well [8]).
Deﬁnitions of PP typically do not account for the appropriateness of medications. PP increases the risk that one or more
medications is “potentially inappropriate”; these potentially
inappropriate medications (PIMs) have risks higher than anticipated beneﬁts in older adults. PIMs may be assessed using
multiple validated instruments including the Beers criteria
[9], Screening Tool of Older Person’s Prescriptions (STOPP)
and Screening Tool to Alert to Right Treatment (START)
criteria [10], Zhan criteria [11], and medication appropriateness index (MAI) [12]. In older adults, PIMs are associated
with increased risks of adverse drug events, hospitalizations,
and mortality [13], as well as higher health care costs [14].
However, supportive care regimens may include medications
(such as benzodiazepines for treatment of nausea) that would
otherwise be deemed PIM but may be clinically appropriate
based on oncology supportive care guidelines.
Although the literature on PP and PIM in older adults is
increasing, data in older adults with cancer remain sparse.
Extrapolation of data from the general population of older
adults is problematic: older adults with cancer have more
frailty and multimorbidity than patients without cancer, they
take more medications on average, and the initiation of chemotherapy and supportive care regimens can signiﬁcantly
increase the risk of drug-drug interactions and adverse drug
events [15]. It also remains unclear whether PP and PIM affect
outcomes in older adults with cancer. This systematic review
and meta-analysis evaluates the association of PP and PIM
with outcomes in older adults with cancer.

MATERIALS AND METHODS
Search Strategy
We followed the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [16]. We
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searched for articles from the following databases between
the database inception and September 2018: PubMed, Web
of Science, Embase, and Cochrane Register of Controlled Trials. Standardized terms and keywords were combined in the
search for the following concepts: oncology/cancer, polypharmacy, and inappropriate medications (supplemental
online Appendix 1). Reference lists of relevant articles were
screened to identify other relevant articles (“snowball” search). All results were exported to EndNote, and duplicates
were identiﬁed and removed.

Selection Criteria
We included studies if they (a) examined any outcomes associated with PP and/or PIM; (b) included patients with cancer
(as either the whole sample or a subgroup); (c) included adults
aged ≥65 (a common cutoff to identify older adults in the literature); (d) were clinical trials, observational cohort studies,
cross-sectional studies, or meta-analyses; and (e) were written
in English. We excluded studies that did not speciﬁcally evaluate the associations of PP and/or PIM with outcomes (i.e.,
studies that described the prevalence of PP and/or PIM only)
and those that were published in abstract form only. Two
investigators (M.M. and A.A.) independently reviewed the
titles and abstracts of retrieved articles to select potential articles. The full texts were further reviewed independently by M.
M. and A.A. for ﬁnal selection of articles. Disagreements
were resolved by a third investigator (K.P.L.).

Data Extraction and Analysis
A predeﬁned data extraction template was developed and
included name of the ﬁrst author, year of publication, country, study design, sample size, age, deﬁnition of PP and PIM,
prevalence of PP and PIM, cancer type, treatment planned
or received, outcome variables, and ﬁndings on the association between PP and PIM and outcome measures. Two independent authors (M.M. and A.A., K.P.L., or S.O.) reviewed
full texts of each identiﬁed article and extracted the data.
After data extraction, outcomes were categorized into
the following domains: postoperative outcomes, chemotherapy outcomes, physical function, survival, and miscellaneous/other outcomes. Odds ratios (OR), p values, and 95%
conﬁdence intervals (CI) were reported for signiﬁcant results
(deﬁned as p < .05 or 95% CI did not cross 1) if available.
Nonsigniﬁcant results are reported as NS, but p values and
OR are not reported as most studies did not report these for
nonsigniﬁcant results.

Meta-Analysis
Studies evaluating the association of PP with postoperative
complications used a consistent deﬁnition of PP (≥5
medications) and postoperative complications (using the
Clavien-Dindo classiﬁcation; n = 4 studies) [17]. We performed a random-effects model to combine the OR and 95%
CI in these four studies. Heterogeneity of included studies
was measured using chi-square test and the I2 statistic, with a
signiﬁcant heterogeneity deﬁned as I2 > 50%. Forest plots
present individual and pooled risk estimates. All statistical
analyses were conducted using Stata 13.0 (Stata Corp, College
Station, TX). Meta-analyses for other outcomes were not
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Figure 1. PRISMA ﬂow diagram. This diagram details our search and study selection process applied during the study according to
PRISMA checklist.

undertaken because of heterogeneity of deﬁnitions of PP
and PIM.

Quality Appraisal
Two independent authors (M.M. and A.A., K.P.L., E.R., or S.O.)
assessed the quality of each selected study. We used the
National Institutes of Health (NIH) Quality Assessment Tool for
Observational Cohort and Cross-Sectional Studies [18] as a
guide. We rated the data quality related to PP and PIM and
outcomes as good, fair, or poor. Disagreements among the
reviewers were discussed and resolved during consensus
meetings.

RESULTS
Study Characteristics
The initial search strategy identiﬁed 3,459 titles and
abstracts. An additional six articles were identiﬁed from the
reference lists of selected articles (Fig. 1). In total, 47 studies
were included (number of patients ranged from 16 to
40,009). These studies were published between 2005 and
2018 from 19 countries. Study designs included retrospective
cohort (23 studies), prospective cohort (14 studies), crosssectional (9 studies), and meta-analysis (1 study). Of these
studies, 46.8% (22/47) included patients with only one cancer type. Common cancer types were gastrointestinal (GI;
24/47, 51.1%), breast (20/47, 42.5%), and lung (8/47, 17%).

© AlphaMed Press 2019

Quality Appraisal
The articles were judged to be good (n = 2, 4.2%), fair (n = 32,
68.1%), or poor quality (n = 13, 27.6%) based on the NIH Quality Assessment Tool (supplemental online Tables 1 and 2). All
studies clearly stated their research objectives and study population. Sample sizes were clearly stated in all studies; however, only two studies provided a justiﬁcation for the sample
size. Only ﬁve studies assessed the exposure more than once.
Based on the authors’ judgment, 19 of the 47 articles did not
adequately adjust for potential confounding variables.

Deﬁnition and Prevalence of PP and PIM
When deﬁning PP, only 19 studies clearly stated which types
of medications were included in their analyses (i.e., prescription, supplemental, and/or over-the-counter medications;
supplemental online Table 1). Overall, the prevalence of PP
ranged from 2.0% to 80.0%. PP was deﬁned as the use of ﬁve
or more medications in 57.4% (27/47) of the studies; in these
studies, the prevalence ranged from 14.0% to 80.0%. Other
deﬁnitions included (a) 10 or more medications (7/47, with
prevalence ranging from 5.6% to 43.0%), (b) 9 or more medications (1/47, with no prevalence reported), (c) 6 or more
medications (3/47, 8.0% to 38.0%), (d) 4 or more medications
(4/47, 49.0% to 86.0%), (e) 3 or more medications (2/47,
43.0% to 52.0%), (f) any concomitant (≥1) medications in addition to cancer treatment (2/47, 2.0%, and 69.0%), and (g)
other deﬁnitions (2/47).
Overall, the prevalence of PIM ranged from 19.0% to
52.0% (assessed in 11/47 studies). Ten of 11 studies used the
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Single center,
prospective cohort

Single center,
retrospective cohort

Population-based
retrospective cohort

Single center,
retrospective cohort

Single center,
retrospective cohort
of prospective data

Kenig, 2015,
Poland [21]

Jeong, 2016,
South Korea [27]

Westley, 2017,
Canada [26]

Fagard, 2017,
Belgium [19]

Choi, 2018, South
Korea [25]

Median: 76 (range ≥5 medications
65–96)
≥10 medications

475

50.5% and 27.9%

47.4%

≥5 medications

Median: 77 (61%
70–79, 39% >80)

Median: 74

Median: 76
(range, 65–96)
31.8% and 5.6%

20.1% (not speciﬁc to
older adults)

≥5 medications

PP: ≥5
medications
EPP: ≥10
medications

13.5%

≥5 medications

50.5%

48.0%

≥5 medications

≥5 medications

26.0%

≥5 medications

190

24,463

475

Mean no. of medications
preoperatively = 6.28,
mean no. of medications
postoperatively = 8.47

≥5 medications

44.0%

PP rate

Deﬁnition of PP

Mean: 73 (SD 5.8; 2 cutoff values
range, 65–93)
were used: ≥4
or ≥ 5
medications

Median: 64
(range, 25–88),
46% were ≥65 yrs

Median: 74
(range, 65–98)

Median: 72
(range, 65–89)

Median: 80
(range, 70–94)

Median: 72
(range, 60–91)

Agea

Any

Colorectal

Breast cancer

Any

GI

Gastric

Breast cancer

GI

Colorectal

Gynecologic
cancers

Cancer type

Cancer surgery

Intra-abdominal
surgery

Curative cancer
surgery

Surgery

Intra-abdominal
surgery

Intra-abdominal
surgery

Breast cancer
surgery

Intra-abdominal
surgery

Surgery

Surgery

Treatment

30-d mortality and
postdischarge
institutionalization

30-d postoperative
complications (CD)

Initial emergency
department visit
within 45 d of
deﬁnitive breast
cancer surgery

Postoperative
delirium

30-d major
postoperative
complications (CD)

Major postoperative
complications (CD),
prolonged hospital
stay >14 d, and
readmission within
30 d of surgery

30-d postoperative
complications

Prolonged hospital
stay, readmission
within 30 days of
surgery, and
discharge to an SNF

30-d major
postoperative
complications (CD)
and survival

Postoperative
delirium

Outcome measures

Postdischarge
institutionalization:
OR, 3.8; 95% CI,
1.04–13.8; p < .05
Other outcome: NS

>5 medications: HR,
1.3; 95% CI, 1.2–1.3;
p < .0001
≥10 medications: HR,
1.5; 95% CI, 1.3–1.8;
p < .0001
NS

≥4 medications: OR,
4.2; 95% CI, 1.4–12.1,
p = NR
≥5 medications: OR,
2.8; 95% CI, 1.1–8.2,
p = NR
NS

OR, 2.4; 95% CI,
1.1–5.2; p = .03
Other outcomes: NS

OR, 1.8; 95% CI,
1.4–2.2; p < .001

Prolonged hospital
stay: OR, 2.5; 95% CI,
1.1–5.5; p = .003
Other outcomes: NS

NS

OR, 1.9; 95% CI, NR;
p = .008

Resultsb

b

Median or mean, SD (range if available).
Multivariate unless otherwise speciﬁed.
Abbreviations: CD, Clavien Dindo; CI, conﬁdence interval; d, day; EPP, excessive polypharmacy; GI, gastrointestinal; HR, hazard ratio; NR, not reported; NS, nonsigniﬁcant; OR, odds ratio; PP, polypharmacy;
SNF, skilled nursing facility.

a

279

Single center,
retrospective cohort

Pujara, 2015, U.S.
[23]

75

3,179

de Glas, 2013, The Multicenter,
Netherlands [28] retrospective cohort

Single center,
prospective cohort

Badgwell, 2013,
U.S. [20]

103

182

Single center,
retrospective cohort

McAlpine, 2008,
Canada [24]

Sample size

Kristjansson,
Multicenter,
2010, Norway [22] prospective cohort

Study design

Study

Table 1. Studies examined the association between PP and postoperative outcomes
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Beers criteria to screen for PIM. Several tools were used in
addition to the Beers criteria including Drugs to Avoid in Elderly
(DAE) list (2/47), STOPP criteria (1/47), HEDIS (1/47), National
Board of Health and Welfare Criteria (1/47), and Zhan (1/47).

Polypharmacy and PIM in Older Adults with Cancer
and hospitalization [30, 31]. PP was not associated with chemotherapy completion, dose reduction, or delay in four studies [37, 38, 40, 41].

Frailty, Falls, and Physical and Functional Outcomes
OUTCOMES
Among all studies, 77.0% (36/47), 6.0% (3/47), and 17.0%
(8/47) investigated outcomes associated with PP, PIM, or
both PP and PIM, respectively. Postoperative outcomes
(e.g., postoperative complications, delirium, extended hospital
stay, and emergency department visit after cancer surgery)
were evaluated in 11/47 studies (23%; Table 1) [19–29]. Chemotherapy-related outcomes, such as chemotherapy-related
toxicities, chemotherapy completion, hospitalization after chemotherapy, complete remission (CR), chemotherapy dose
reductions or delay, and blood transfusion, were evaluated
in 12/47 studies (26%; Table 2) [30–41]. Frailty, falls, and
physical and functional outcomes were evaluated in 7/47
studies (15%; Table 3) [42–48]. Survival outcomes were
assessed in 12/47 studies (26%; Table 4) [22, 29, 30, 34, 36,
37, 49–54]. Other outcomes (e.g., medication adherence,
caregiver burden and alternative medications use; supplemental online Table 3) [32, 39, 49, 53, 55–63].

Postoperative Outcomes
See Table 1. A meta-analysis of four studies (n = 726 patients
with GI cancers) [19, 21–23] indicated a signiﬁcant association between PP and postoperative complications (overall
OR, 1.9; 95% CI, 1.3–2.8; p = .001; Fig. 2). A study assessing
the relationship between PP and postoperative delirium
found that patients with gynecologic malignancies who
received ﬁve or more medications before cancer surgery
were at a higher risk of postoperative delirium (OR, 1.9; 95%
CI, not reported [NR]; p = .008) [24].

Chemotherapy-Related Outcomes
See Table 2. Of the 12 studies that examined the association
between PP and chemotherapy-related outcomes, 9 evaluated
chemotherapy toxicity [31–34, 36, 37, 39–41]. The cancer
types and treatments in these studies were heterogeneous.
Four studies demonstrated that PP was signiﬁcantly associated
with severe chemotherapy toxicity [33, 36, 37, 39]. In a metaanalysis of three phase II/III trials by Woopen et al. that
included 1,213 patients with advanced ovarian cancer, PP (≥5
medications) was associated with grade 3–4 hematological
and nonhematological toxicities (OR, 1.1; 95% CI, NR; p < .001)
[37]. In a single-center prospective study of 78 patients with
breast cancer receiving ﬁrst-line chemotherapy, PP (≥5 medications) was associated with grade 3–4 toxicities (OR, 6.38; 95%
CI, 2.0–23.5; p = .001) [36]. In a single center retrospective
study of 172 patients with solid tumors receiving irinotecanbased therapy, the presence of any concomitant drug used to
manage comorbid conditions besides cancer was associated
with grade 4 neutropenia and/or grade 3–4 diarrhea (OR, 4.7;
95% CI, 1.04–21.3; p = .04) [33]. PP (≥6 medications) was also
associated with hospitalization (OR, 2.3; 95% CI, 1.3–3.9;
p = .002) in a single center retrospective study of 318 patients
with solid tumors receiving chemotherapy [40]. Two additional
studies did not demonstrate any association between PP
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See Table 3. Seven studies examined the association between
PP and frailty, falls, or physical and functional outcomes.
Three studies demonstrated a positive association between
PP and falls [44, 47, 48]. PP was associated with impairment
in either Activity of Daily Living or Instrumental Activity of
Daily Living in three studies [43, 45, 46]. In a single center
cross-sectional study of 385 older patients with various types
of cancers (both solid and hematological), PP (≥5 medications) was associated with frailty (OR, 4.5; 95% CI, 1.9–10.5;
p = NR) and prefrailty (OR, 2.4; 95% CI, 1.4–3.9; p = NR) [42].

Survival Outcomes
See Table 4. Only two studies demonstrated a positive association between PP and mortality [30, 52]. In a single-center
prospective study of 83 patients with advanced ovarian cancer, PP (≥6 medications) was associated with lower overall
survival (OS; OR, NR; 95% CI, NR; p = .04) [52]. In another
single center retrospective study of 150 patients with acute
myeloid leukemia, PP (≥5 medications) was associated with
increased 30-day mortality (OR, 9.98; 955 CI, 1.18–84.13;
p = NR) and overall mortality (hazard ratio [HR], 2.13; 95%
CI, 1.15–3.92; p = NR) [30].

Other Outcomes
See supplemental online Table 3. Of the four studies evaluating medication adherence, three demonstrated an association
of PP with adherence [39, 55, 57]. In a single center prospective study of 47 patients with breast cancer, PP (≥4 medications) was associated with patients receiving nonoperative
radiotherapy despite being a candidate for surgery on univariate analysis (no multivariate analysis was done; OR, NR; 95%
CI, NR; p = .002) [59]. In another multicenter cross-sectional
study, PP was associated with clinical depression (OR, 1.6; 95%
CI, 1.1–2.3; p = .008) [60]. PP was also associated with use of
complementary and alternative medications (OR, NR; 95% CI,
NR; p = .04) and caregiver burden (OR, 2.2; 95% CI, 1.1–4.3;
p = .02) [58, 62]. PP was not associated with impaired geriatric
assessment domains using the Geriatric 8 screening tool, nor
with radiation treatment completion or change in cancer treatment plan [49, 53, 63].

Association of PIM with Outcomes
See Table 5. Among 11 studies [25, 27, 29–32, 45, 54, 58, 64,
65], three demonstrated an association between PIM and clinical outcomes. In a single center retrospective study of 171
patients with aggressive non-Hodgkin lymphoma, PIM use by
Beers criteria was associated with grade ≥ 3 toxicity (HR, 1.02;
95% CI, 1.00–1.04; p = .01), worse progression-free survival
(HR, 2.81; 95% CI, 1.4–5.8; p = .005), and higher mortality (HR,
3.12; 95% CI, 1.5–6.5; p = .003) [64]. In another single center
retrospective study of 475 patients (Beers criteria), PIM was
associated with postoperative delirium (OR, 5.53; 95% CI,
2.02–15.10; p < .001) [27]. A retrospective study that included
7,279 patients with colorectal cancer who underwent cancer
surgery identiﬁed an association between PIM (using the
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Single center,
retrospective
cohort

Multicenter,
retrospective
cohort

Iurlo, 2016,
Italy [34]

Single center,
retrospective
cohort

Sud, 2015,
Canada [40]

Park, 2016,
Korea [32]

Single center,
cross-sectional
study

Ting, 2015,
Singapore [39]

39.8%

62.9%

38%

≥6 medications

≥5 medications

≥6 medications

Mean: 79.4

36.1%

43.7%

≥3 medications

≥5 medications

≥5: 38.0%

≥5 medications
≥4 medications

296

49.0% and 11.0%

≥4 medications
≥10 medications

29.3%

51.0%

≥5 medications

Median: 73
≥5 medications
(range, 65– 87)

Median: 82
(range, 80–92)

Solid tumors

69.0%

Any concomitant
drug used to
manage comorbid
conditions besides
cancer

Chronic
myeloid
leukemia

Head and neck
cancers

Solid tumors

Any cancer

Any cancer

Chronic
myeloid
leukemia

Acute myeloid
leukemia

Solid tumors

Breast cancer

Cancer type

PP rate

Deﬁnition of PP

229

318

Mean: 71.8

Single center,
retrospective
cohort

Kim, 2014,
South Korea
[38]

294

Median: 72
(range, 65–88)

16

Single center,
retrospective
cohort

Iurlo, 2014,
Italy [35]

87.8% >70

Median: 69
(range, 61–87)

150

Single center,
retrospective
cohort

Elliot, 2014,
U.S. [30]

98

Median not
reported: 54%
≥72

500

Multicenter,
retrospective
cohort

Maggiore,
2014, U.S. [31]

Median: 64
(range, 31–78)

Median: 76
(range, 66–87)

172
(71% ≥65)

Agea

78

Single center,
retrospective
cohort

Sasaki, 2013,
Japan [33]

Sample size

Hamaker, 2013, Single center,
The
prospective study
Netherlands
[36]

Study design

Study

Table 2. Studies examined the association between PP and chemotherapy-related outcomes

Imatinib

Surgery, radiotherapy, or
chemo-radiation

Chemotherapy

Outpatient chemotherapy

Palliative chemotherapy

Imatinib

Induction chemotherapy

Outpatient chemotherapy

First-line chemotherapy

Irinotecan-based therapy

Treatment

NS

CCR: 4/7 patients with PP
vs. 5/9 patients without
PPc
Change of chemotherapy
regimen: 2/7 patients with
PP vs. 3/9 patients without
PPc

CR status: OR, 0.2; 95% CI,
0.1–0.6; p = NR
Other outcomes: NS

NS

OR, 6.4; 95% CI, 2.0–23.5;
p = .001

OR, 4.7; 95% CI, 1.04–21.3;
p = .04

Resultsb

CCR, event-free survival,
and toxicities

Grade 3–4 toxicity and
hospitalization

NS

NS

(continued)

Hospitalization: OR, 2.3;
Rate of discontinuation
due to toxicity, rate of dose 95% CI, 1.3–3.9; p = .002
reduction/ omission/delay, Other outcomes: NS
hospitalization, and blood
transfusion

OR, 3.2; 95% CI, 1.4–7.3;
Drug-related problems
p = .006
(potential drug
interactions, adverse
events, and nonadherence)

Early discontinuation of
chemotherapy

CCR and change of
chemotherapy regimen

CR status, prolonged
hospital stay, and ICU
admission

Chemotherapy-related
toxicity and hospitalization

Grade 3–4 toxicity

Severe toxicity (grade 4
neutropenia and/or grade
3/4 diarrhea)

Outcome measures
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Single center,
prospective cohort

Median or mean, SD (range if available).
Multivariate unless otherwise speciﬁed.
No analysis, only absolute numbers were reported.
Abbreviations: CI, conﬁdence interval; CCR, complete cytogenic response; CR, completer response; HR, hazards ratio; ICU, intensive care unit; NR, not reported; NS, nonsigniﬁcant; OR, odds ratio; PP, polypharmacy.
c

b

a

Adjuvant chemotherapy with
or without radiotherapy
64%
≥6 medications
Mean: 79.6
(range, 75–89)
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193
Antonio, 2018,
Spain [41]

Colorectal
cancer

Treatment refusal, grade 3 Treatment refusal: OR, 5.3;
toxicity, and completion of 95% CI, 1.6–18.4; p = .01
at least 80% of the planned Other outcomes: NS
chemotherapy dose

Overall grade 3–4
toxicities: OR, 1.1; 95% CI,
NR; p < .001
Grade 3–4 hematological
toxicities: OR, 1.056; 95%
CI, NR; p < .001
Severe nonhematological
toxicity: OR, 1.1; 95% CI,
NR; p < .001
Other outcomes: NS
Overall grade 3–4
toxicities, grade 3–4
hematological and
nonhematological toxicity,
and early discontinuation
of chemotherapy
Various chemotherapy
regimens
Advanced
ovarian cancer
56.3%
≥5 medications
Median: 59
(range, 21–83)
Woopen, 2016, Meta-analysis (the 1,213 (% older
adults not
Germany [37]
original patient
data of three phase reported)
II/III trials)

Treatment
PP rate
Deﬁnition of PP
Study design
Study

Table 2. (continued)

Sample size

Agea

Cancer type

Outcome measures

Resultsb

e100

National Board of Health and Welfare criteria) [66] and
length of hospital stay (OR, 1.1; 95% CI, 1.0–1.3;
p = .046) and 30-day postoperative mortality (OR, 1.4;
95% CI, 1.1–1.9; p = .006) [29].

DISCUSSION

To the authors’ knowledge, this is the ﬁrst systematic
review that summarizes the associations of PP/PIM with
outcomes in older adults with cancer. Included studies
were heterogeneous in terms of study design, study population, sample size, PP deﬁnitions, and outcomes examined. The wide range of deﬁnitions used contributes to the
wide range of PP prevalence reported, from 2% [56] to
80% [45]. PIMs were assessed using the Beers criteria in
the vast majority of the studies, which is the most commonly used tool for evaluation of PIMs in both clinical and
research settings; other tools supplemented the use of the
Beers criteria in some studies.
The meta-analysis shows that PP is associated with
postoperative complications using the Clavien-Dindo classiﬁcation. In addition, several studies suggest that PP is associated with chemotherapy toxicity, frailty, falls, and
medication nonadherence. Most studies did not show
an association between PP and survival, and no studies
showed an association between PP and chemotherapy
completion. PIM is associated with postoperative complications (delirium and readmission), and two studies
indicate that PIM may be associated with higher mortality
and lower progression-free survival [29, 64].

Most studies did not show an association between
PP and survival, and no studies showed an
association between PP and chemotherapy completion. PIM is associated with postoperative complications (delirium and readmission), and two studies
indicate that PIM may be associated with higher
mortality and lower progression-free survival.

Other reviews in the general geriatric population have
found a positive association of PP with functional decline
[67, 68]. However, this is the ﬁrst systematic review to
summarize the association between PP and postoperative
outcomes and chemotherapy toxicity in older adults with
cancer. Because of increased frailty and geriatric syndrome
burden in older adults with cancer, as well as the contribution of chemotherapy and supportive care regimens to the
overall number of medications, data from general older
adult populations are unlikely to be generalizable.
Four studies assessing the impact of PP on postoperative outcomes used a similar population (patients with gastrointestinal cancers), the same deﬁnition of PP (≥5
medications), and the same outcome (postoperative complications using the Clavien-Dindo classiﬁcation). A pooled
analysis of these studies demonstrated that PP was associated with postoperative complications, with an overall OR
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Single center,
cross- sectional
study

Multicenter,
prospective
cohort

Single center,
cross-sectional
study

Multicenter,
cross-sectional
study

Single center,
cross- sectional
study

Multicenter, crosssectional study

Multicenter,
retrospective
cohort

Prithviraj, 2012,
U.S. [45]

Vande Walle,
2014, Belgium
[48]

Turner, 2014,
Australia [42]

Williams, 2015,
U.S. [47]

Turner 2016,
Australia [44]

Pamoukdjian
2017, France [46]

van Abbema,
2017, The
Netherlands [43]

Mean: 80.6
Median: 60
(range, 50–69 y)
Median in
patients aged ≥70:
75 (range, 70–93)

837 (21.4% ≥70)

Median: 76.7
(range, 70–92)

385

290

Mean: 73 (range,
65–99)

Median: 76.7
(range, 70–92)

Median: 76
(range, 70–95)

Mean: 74.6
(range, 65–85)

Agea

1,172

385

937

117

Sample size

PP rate
80.0%

53.1%

57.0%

Not reported

57.0%

67.4%
26.8% in patients
aged ≥70

Deﬁnition of PP
≥5 medications

≥5 medications
≥5 medications

≥9 medications
≥5 medications

≥5 medications
≥5 medications

Breast and
colorectal cancers

Any cancer except
HCC

Any cancer

Any cancer

Any cancer

Any cancer

Solid tumors

Cancer type

Surgery

Not speciﬁed

Not speciﬁed

Not speciﬁed

Not speciﬁed

Not speciﬁed

Chemotherapy

Treatment

Functional status
(ADL, IADL, and
combined)

Disability (impairment
in ADL and/or IADL)

Falls, physical
impairment, and
frailty

Falls

Physical impairment,
frailty, and prefrailty

Falls

IADL and VES score

Outcome measures

ADL: OR, 2.1; 95%
CI, 1.1–3.8; p = NR
IADL: OR, 1.9;
95% CI, 1.1–3.4;
p = NR
Combined ADL
and IADL: OR, 2.1;
95% CI, 1.3–3.5;
p = NR

≥5.5 medications
was associated
with increased
fallsc
≥6.5 medications
was associated
with physical
impairment and
frailtyc
OR, 2.3; 95% CI,
1.01–4.4; p = .04

Physical
impairment: OR,
1.1; 95% CI,
1.1–1.2; p = NR
Frail: OR, 4.5; 95%
CI, 1.9–10.5;
p = NR
Prefrail: OR, 2.4;
95% CI, 1.4–3.8;
p = NR
OR, 1.6; 95% CI,
1.2–2.3; p < .001

IADL: OR, NR; 95%
CI, NR; p = .007
(univariate only)
VES score: OR,
NR; 95% CI, NR;
p = .03 (univariate
only)
PP was associated
with IADL and VES
score impairment
NS

Resultsb

b

Median or mean, SD (range if available).
Multivariate unless otherwise speciﬁed.
c
Odds ratio and p value were not reported (sensitivity and speciﬁcity values).
Abbreviations: CI, conﬁdence interval; ADL, activity of daily living; IADL, instrumental activity of daily living; HCC, hepatocellular carcinoma; NR, not reported; NS, nonsigniﬁcant; OR, odds ratio; PP, polypharmacy; VES, Vulnerable Elders-13 Survey.

a

Study design

Study

Table 3. Studies examined the association between PP and frailty, falls, and physical and functional outcomes
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78

111

Single center,
prospective
study

Multicenter
phase II clinical
trial

Hamaker, 2013,
The
Netherlands
[36]
Falandry, 2013,
France [51]
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Iurlo, 2016, Italy Multicenter,
[34]
retrospective
cohort

296

287

1,213

Woopen, 2016,
Germany [37]

Caparrotti,
2016, Canada
[50]

150

Elliot, 2014, U.S. Single center
[30]
retrospective
cohort

Meta-analysis
the original
patient data of
three phase
II/III trials
Single center,
retrospective
cohort

108

Hamaker, 2014, Single center,
The
retrospective
Netherlands
cohort
[49]

182

Multicenter,
prospective
cohort

Kristjansson,
2010, Norway
[22]

Sample size
83

Study design
Single center,
prospective
cohort

Study
Freyer, 2005,
France [52]

Mean: 79.4

Median: 74–75

Median: 62

Median: 69
(range, 61–87)

Median: 78.2
(range,
67.1–98.9)

Median: 79
(range, 71–93)

Median: 76
(range, 66–87)

Median: 80
(range, 70–94)

Agea
Median: 76

Colorectal

26.0%

51.0%

68.0%

65.0%

≥5: 38.0%

56.0%

≥5 medications

≥5 medications

≥4 medications
≥5 medications

≥5 medications
≥4 medications

≥6 medications

Chronic myeloid Imatinib
leukemia

≥5 medications

36.0%

Oropharyng-eal Deﬁnitive
cancer
radiation
(chemotherapy
is allowed)

Chemotherapy

Standard
treatment,
adjusted
treatment, or
no treatment
Induction
chemotherapy

First-line
carboplatin

First-line
chemotherapy

Surgery

Treatment
First-line
palliative
chemotherapy

Comorbidity-PP 47.0%
score (sum of
comorbidity and
medications), 6
or more

Ovarian cancer

Acute myeloid
leukemia

Hematologic
cancer

Ovarian cancer

Breast cancer

Cancer type
Ovarian cancer

Deﬁnition of PP PP rate
≥6 medications 8.0%

Table 4. Studies examined the association between PP and survival outcomes

NS

NS

NS

Results
PP was
associated with
lower OS
(p = .04)b
NS

OS (from date
of imatinib
initiation)

5-year OS

NS

NS

(continued)

30-day
mortality: OR,
9.9; 95% CI,
1.2–84.1,
p = NR
Overall
mortality: HR,
2.1; 95% CI,
1.2–3.9; p = NR
Progression-free NS
survival and
5-year OS

30-d mortality
and overall
mortality

1-y mortality

OS

OS

30-d major
postoperative
complication
(CD) and
survival

Outcome
measures
40-mo OS
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NS

e103

mortality
Adjuvant
chemotherapy
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b

Median or mean, SD (range if available).
Odds ratio was not reported.
Abbreviations: CI, conﬁdence interval; HR, hazard ratio; NR, not reported; NS, nonsigniﬁcant; PP, polypharmacy; OS, overall survival.

Figure 2. Meta-analysis. Forest plot for a meta-analysis of studies evaluated the association of polypharmacy (≥5 medications)
and postoperative complications (using the Clavien-Dindo classiﬁcation).
Abbreviation: CI, conﬁdence interval.

a

Breast and
colorectal
cancers
Breast: 55.4%
≥5 medications 41.4% and
>70 years
≥11 medications 31.0%
Colorectal: 63%
>70 years
3,123 (1848 > 70 years)
Karuturi, 2018,
U.S. [54]

Study design
Single center,
retrospective
cohort
Populationbased
retrospective
cohort
Study
Nieder, 2017,
Norway [53]

Table 4. (continued)

Sample size
280

Agea
Median: 77
(range, 70–95)

Deﬁnition of PP PP rate
≥5 medications 7.03%

Cancer type
Any cancer

Treatment
Palliative
radiation

Outcome
measures
30-d mortality
and OS

Results
NS

Mohamed, Ramsdale, Loh et al.

of 1.9 (95% CI, 1.3–2.8). This may be due to an increased risk
of adverse drug events and drug-drug interactions in the
presence of anesthetic and other perioperative medications
such as analgesics and antibiotics. In addition, hospitalization
itself is associated with an increased risk of postdischarge
medication-related adverse events [69]. We are unable to
determine which medications or class of medications were
most associated with postoperative complications; medications assessed as being potentially inappropriate by Beers
criteria or other PIM measures have shown associations with
postoperative length of stay, mortality, and postoperative
delirium across several studies [27, 29], but the effect of PIM
on postoperative complications in older patients with cancer
is unknown.
Similarly, the association between PP and chemotherapy
outcomes remains unclear. Several studies demonstrate that
PP is associated with grade ≥ 3 chemotherapy toxicity, but
other studies failed to show an association with chemotherapy
dose intensity or early discontinuation of therapy. It remains
unclear whether PP affects receipt of chemotherapy and, in
turn, cancer-related survival. This question may be most critical in older patients being treated with curative intent, for
whom chemotherapy dose delays or reductions may substantially affect survival outcomes. PP increases the risk of clinically
relevant drug-drug interactions which may potentiate chemotherapy toxicity and/or adverse drug events [70].
PP was found to be signiﬁcantly associated with reduced
OS in only 2 out of 11 studies [30, 52]. The lack of association in other studies may be due to the advanced stage of
cancer and poor overall prognosis of the included patients.
In very sick patients, PP may be appropriate and may serve
to prolong survival [71]. Competing risk of cancer mortality
is also possible: patients with advanced cancer may die
from their cancer before the adverse effects of PP accrue.
Among the other outcomes evaluated, PP was associated
with improved adherence to adjuvant endocrine therapy [55],
except among patients frequently using opioid-containing analgesics, anxiolytics or antipsychotics, and antidepressants who
had lower adherence to their cancer therapy. This suggests that
certain drug classes may have a disproportionate effect on outcomes and that a simple count of medications to assess PP
may incorrectly assess risk. Adherence is an important predictor
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Populationbased,
retrospective
cohort

Single center,
retrospective
cohort of
prospective
data

Populationbased
retrospective
cohort

Samuelsson,
2016, Sweden
[29]

Choi, 2018,
South Korea
[25]

Karuturi, 2018,
U.S. [54]

Median: 81
(range, 75–98)

Median: 76
(range, 65–96)

Breast: 55.4%
>70
Colorectal: 63%
>70

475

3,123
(59% >70)

Median: 73
(range, 65–87)

7,279

229

Single center,
retrospective
cohort

Park, 2016,
Korea [32]

Median: 76
(range, 65–96)

475

Single center,
retrospective
cohort

Jeong, 2016,
South Korea
[27]

Nightingale,
2015, U.S. [58]

36%

Breast: 27.6%
(Beers 2015)
and 22% (DAE
list)
Colorectal:
24.8% (Beers
2015) and
15.5% (DAE
list)

Beers 2015 and
DAE list

22.5%

24%

26.7%

51.7%
(combined)

28.3%

Beers (29%),
Zhan (11%),
DAE (13%)

19%

41%

PIM rate

Beers 2015

National Board of
Health and
Welfare criteria

Beers 2012

Beers 2012

Beers 2012,
STOPP, and HEDIS

Beers 2012

Beers, Zhan, and
2011 DAE list

54% ≥72

Mean: 79.9
(range, 61–98)

Single center,
retrospective
cohort

Chiang, 2015,
U.S. [65]

500

Beers 2012

Beers 2013

Deﬁnition of PIM

Median: 69
(range, 61–87)

234

Multicenter,
retrospective
cohort

Maggiore,
2014, U.S. [31]

150

Single center,
crosssectional
study

Single center,
retrospective
cohort

Elliot, 2014,
U.S. [30]

Mean: 74.6
(range, 65–85)

117

Median: 72.7
(SD, 6.4)

Single center,
crosssectional
study

Prithviraj,
2012, U.S. [45]

Agea

Sample size

677

Study design

Study

Table 5. Studies examined the outcomes associated with PIM

Cancer surgery

Adjuvant
chemotherapy

Breast and
colorectal
cancers

Cancer surgery

Surgery, radiotherapy,
or chemo-radiation

Surgery

Any

Not speciﬁed

Outpatient
chemotherapy

Induction
chemotherapy

Chemotherapy

Treatment

Any

Colorectal
cancer

Head and neck
cancers

Any

Any cancer

Any

Solid tumors

Acute myeloid
leukemia

Solid tumors

Cancer type

Emergency room visit,
hospitalization, and death

30-d mortality and
postdischarge
institutionalization

Length of hospital stay
and 30-d postoperative
mortality

Grade 3–4 toxicity and
hospitalization

Postoperative delirium

CAM use

Unplanned admission to
any hospital for any
reason within 30 d of
discharge from the index
hospital stay

Chemotherapy-related
toxicity and
hospitalization

30-d mortality, CR status,
prolonged hospital stay,
and ICU admission

IADL and VES-13 score

Outcome measures

NS

(continued)

Length of hospital
stay: OR, 1.1; 95% CI,
1–1.3; p = .046
30-d postoperative
mortality: OR, 1.4;
95% CI, 1.1–1.9;
p = .006
NS

NS

OR, 5.5; 95% CI,
2.0–15.1, p < .001

NS

NS

NS

NS

NS

Resultsb
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b

Median or mean, SD (range if available).
Multivariate unless otherwise speciﬁed.
Abbreviations: CAM, complementary alternative medicine; CI, conﬁdence interval; CR, complete response; DAE, drugs to avoid in the elderly; HR, hazard ratio; IADL, instrumental activity of daily living; ICU,
intensive care unit; NS, nonsigniﬁcant; OR, odds ratio; OS: overall survival; PFS, progression-free survival; PIM, potentially inappropriate medications; VES, Vulnerable Elders-13.
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a

Grade 3–4 toxicity:
HR, 1.02; 95% CI,
1–1.04; p = .014
PFS: HR, 2.8; 95% CI,
1.4–5.8; p = .005
OS: HR, 3.1; 95% CI,
1.5–6.5; p = .003
Other outcomes: NS
Treatment delay, dose
reductions, grade 3–4
toxicity, PFS, OS
Chemoimmunotherapy
Aggressive
non-Hodgkin
lymphoma
47%
Beers 2015
Median: 70
(range, 65–77)
171
Single center,
retrospective
cohort
Lin, 2018, U.S.
[64]

Agea
Sample size
Study design
Study

Table 5. (continued)

Deﬁnition of PIM

PIM rate

Cancer type

Treatment

Outcome measures

Resultsb
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of clinical outcomes [72], and more data are needed to assess
the effects of PP, PIM, and medication burden on adherence,
particularly for the increasing number of oral chemotherapy agents [73]. It is also possible that medication burden
could impair patients’ ability to adhere to supportive care
regimens, thereby adversely affecting outcomes, but no
data speciﬁcally evaluates this hypothesis.
There are limited studies evaluating the association of PIM
with clinical outcomes, and most did not show signiﬁcant associations. Existing criteria and tools to determine PIM are primarily derived from the general geriatric population [74, 75],
and the applicability of these tools in the setting of cancer is
unclear. The time frame for identiﬁcation of PIM in patients
with cancer may be problematic: many are prescribed supportive care medications considered potentially inappropriate in
older adults, although these are usually administered transiently and may be speciﬁcally appropriate to treat symptoms
related to cancer or cancer treatment. One study has noted a
transient elevation in PIM prevalence after a lung or colon cancer diagnosis, which was mostly due to the use of supportive
care medications [76]. Most current PIM assessment tools consist of explicit criteria which account for little patient context;
assessment of the appropriateness of medications could be
improved with tools using implicit criteria, such as the MAI, but
such tools require time and expertise for application. The MAI
assesses the appropriateness of all medications on a patient’s
list: any medication may be inappropriate within a certain context (such as lack of an ongoing indication for the medication
or lack of time to beneﬁt based on life expectancy).
Two population-based studies were published after our
search and were not included in our systematic review. The
ﬁrst found an association of PIM (using Beers criteria) with
greater health care utilization and higher health care costs in
a cohort of 17,630 older patients with breast, colorectal, and
prostate cancers [77]. Another study of 3,123 older patients
with breast and colorectal cancers did not ﬁnd an association
between PIM (using STOPP criteria) and emergency department visits, hospitalization, or death [78].
Despite some limited data suggesting that PP/PIM can
affect outcomes in older adults with cancer, it is unknown
whether intervening on PP or PIM can improve outcomes.
There is growing interest in “deprescribing” interventions,
involving planned withdrawal of medications. Deprescribing
has been shown in preliminary studies to reduce the number
of PIMs, falls, and mortality in certain populations. Although
deprescribing has been shown to be feasible in older adults
with cancer, data are lacking about its efﬁcacy [79, 80].

Deprescribing has been shown in preliminary studies
to reduce the number of PIMs, falls, and mortality in
certain populations. Although deprescribing has
been shown to be feasible in older adults with
cancer, data are lacking about its efficacy.

More studies are needed to determine the prospective outcomes of targeted deprescribing interventions (whether
decreasing PP will improve outcomes of interest) as well as
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determine how these interventions can be implemented for
older adults with cancer, including who should deliver them
(oncologist, pharmacist, or other health care provider).
This review underscores the limited data available to
assess the impact of PP and PIM on outcomes for older
adults with cancer. Prospective data are limited; most studies
are retrospective cohort or cross-sectional studies. Many
studies were not designed with the speciﬁc objective to evaluate the effects of PP and PIM on outcomes. Many studies
included PP and/or PIM as one of many covariates assessed
(in the setting of geriatric assessment, for example), rather
than as the primary variable of interest; this approach may
be suboptimal for confounding controls and may lead to misinterpretation and lack of reproducibility [81]. The studies
are not consistent in their deﬁnitions of PP, and most of the
included studies did not specify how they counted the number of medications. Many medications contributing to the
risk of adverse outcomes are over-the-counter (e.g., diphenhydramine) or are typically prescribed on an as needed basis
(e.g., benzodiazepines). Omission of these groups of medications from the assessment could limit the validity and applicability of the data. In addition, patients who are on more
medications are more likely to have more comorbidities
and/or functional decline, which are important confounders
to consider as they may lead to adverse outcomes; although
some papers adjusted for these factors, it was not always
possible to determine the independent contribution of PP
and PIM. Finally, included studies were not limited to those
enrolling only older adults, most did not assess the potential
for interaction between age and PP and PIM, and studies
included subjects with variable cancer types and other characteristics, which may carry different risks of adverse
outcomes.
Our study has several additional limitations. We did not
include non-English publications, and six studies were not
identiﬁed in the initial search, so it is possible that other
studies were missed. Most of the studies were perceived to
have poor to fair quality in relation to the speciﬁc objective
of this review. The majority were retrospective or cross-sectional in design, and the causal relationships between PP and
the various outcomes cannot be determined. Most studies
(27/47) evaluated PP in the context of a geriatric assessment
(GA) and included limited information on the medications
(e.g., classes, doses). We were unable to determine if the
results of the GA were available to treating physicians; GA is
known to inﬂuence discussion about medications and may
drive medication changes, which in turn may affect outcomes of interest [82]. Although the majority of the included

studies provided quantitative deﬁnition of PP, only about
one-third clearly speciﬁed whether prescription, supplemental, and over-the-counter medications were included.

CONCLUSION
This is the most comprehensive review to date assessing
associations between PP and/or PIM and health outcomes in
older patients with cancer. PP and PIM are prevalent in older
adults with cancer, but deﬁnitions are very heterogeneous,
complicating interpretability of associations with outcomes
of interest. PP is associated with postoperative complications, functional impairment and possibly chemotherapyrelated toxicity, although prospective studies with detailed
medication reviews are needed to further investigate these
associations. Data are very limited for associations with PIM
and outcomes in older patients with cancer, and widely-used
PIM measures may not be as useful in this population. Clear
and validated deﬁnitions and instruments are needed to
investigate PP and PIM in older adults with cancer and to
develop interventions, such as deprescribing interventions,
to improve outcomes for these vulnerable patients.

ACKNOWLEDGMENTS
The work was funded through R01 CA177592 (S.G.M.), K24
AG056589 from the National Institute of Aging (S.G.M.), and
a Wilmot Fellowship Award (E.R.). All statements in this
report, including its ﬁndings and conclusions, are solely those
of the authors and do not necessarily represent the ofﬁcial
views of the funding agencies. The study was presented as a
poster presentation at the 2018 International Society of Geriatric Oncology Annual Meeting.

AUTHOR CONTRIBUTIONS

Conception/design: Mostafa R. Mohamed, Erika Ramsdale, Kah Poh Loh,
Supriya G. Mohile
Collection and/or assembly of data: Mostafa R. Mohamed, Kah Poh Loh,
Asad Arastu, Spencer Obrecht
Data analysis and interpretation: Mostafa R. Mohamed, Erika Ramsdale,
Kah Poh Loh, Huiwen Xu, Daniel Castillo
Manuscript writing: Mostafa R. Mohamed, Erika Ramsdale, Kah Poh Loh,
Manvi Sharma
Final approval of manuscript: Mostafa R. Mohamed, Erika Ramsdale, Kah
Poh Loh, Asad Arastu, Huiwen Xu, Spencer Obrecht, Daniel Castillo, Manvi
Sharma, Holly M. Holmes, Ginah Nightingale, Katherine M. Juba, Supriya
G. Mohile

DISCLOSURES
The authors indicated no ﬁnancial relationships.

REFERENCES
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7–30.

older adults: a longitudinal study from England.
BMJ Open. 2017;7:e016358.

2. Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther
2009;85:86–88.

5. Jensen GL, Friedmann JM, Coleman CD et al.
Screening for hospitalization and nutritional risks
among community-dwelling older persons. Am J
Clin Nutr 2001;74:201–205.

3. Mohile SG, Fan L, Reeve E et al. Association of
cancer with geriatric syndromes in older Medicare
beneﬁciaries. J Clin Oncol 2011;29:1458–1464.
4. Dhalwani NN, Fahami R, Sathanapally H et al.
Association between polypharmacy and falls in

© AlphaMed Press 2019

6. Leelakanok N, Holcombe AL, Lund BC et
al. Association between polypharmacy and
death: A systematic review and meta-analysis.
J Am Pharm Assoc (2003) 2017;57:729–
738.e10.

7. Masnoon N, Shakib S, Kalisch-Ellett L et al.
What is polypharmacy? A systematic review of
deﬁnitions. BMC Geriatr 2017;17:230.
8. Nightingale G, Hajjar E, Swartz K et al. Evaluation of a pharmacist-led medication assessment
used to identify prevalence of and associations
with polypharmacy and potentially inappropriate
medication use among ambulatory senior adults
with cancer. J Clin Oncol 2015;33:1453–1459.
9. American Geriatrics Society 2019 Updated
AGS Beers Criteria for Potentially Inappropriate

Mohamed, Ramsdale, Loh et al.
Medication Use in Older Adults. J Am Geriatr Soc
2019;67:674–694.
10. O’Mahony D, O’Sullivan D, Byrne S et al.
STOPP/START criteria for potentially inappropriate prescribing in older people: Version 2. Age
Ageing. 2015;44:213–218.
11. Zhan C, Sangl J, Bierman AS et al. Potentially
inappropriate medication use in the communitydwelling elderly: Findings from the 1996 Medical
Expenditure Panel Survey. JAMA 2001;286:2823–
2829.
12. Hanlon JT, Schmader KE. The medication
appropriateness index at 20: Where it started,
where it has been, and where it may be going.
Drugs Aging 2013;30:893–900.
13. Klarin I, Wimo A, Fastbom J. The association
of inappropriate drug use with hospitalisation
and mortality: A population-based study of the
very old. Drugs Aging 2005;22:69–82.
14. Stockl KM, Le L, Zhang S et al. Clinical and
economic outcomes associated with potentially
inappropriate prescribing in the elderly. Am J
Manag Care 2010;16:e1–e10.
15. Popa MA, Wallace KJ, Brunello A et al.
Potential drug interactions and chemotoxicity in
older patients with cancer receiving chemotherapy. J Geriatr Oncol 2014;5:307–314.
16. Moher D, Shamseer L, Clarke M et al. Preferred reporting items for systematic review and
meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
17. Dindo D, Demartines N, Clavien PA. Classiﬁcation of surgical complications: A new proposal
with evaluation in a cohort of 6336 patients and
results of a survey. Ann Surg. 2004;240:205–213.
18. National Institutes of Health. Quality assessment tool for observational cohort and crosssectional studies. Available at https://www.nhlbi.nih.
gov/health-pro/guidelines/in-develop/cardiovascularrisk-reduction/tools/cohort. Accessed February 1,
2018.
19. Fagard K, Casaer J, Wolthuis A et al. Value of
geriatric screening and assessment in predicting
postoperative complications in patients older than
70 years undergoing surgery for colorectal cancer.
J Geriatr Oncol 2017;8:320–327.
20. Badgwell B, Stanley J, Chang GJ et al. Comprehensive geriatric assessment of risk factors
associated with adverse outcomes and resource
utilization in cancer patients undergoing abdominal surgery. J Surg Oncol 2013;108:182–186.
21. Kenig J, Olszewska U, Zychiewicz B et al.
Cumulative deﬁcit model of geriatric assessment
to predict the postoperative outcomes of older
patients with solid abdominal cancer. J Geriatr
Oncol 2015;6:370–379.
22. Kristjansson SR, Jordhøy MS, Nesbakken A
et al. Which elements of a comprehensive geriatric assessment (CGA) predict post-operative complications and early mortality after colorectal
cancer surgery? J Geriatr Oncol 2010;1:57–65.
23. Pujara D, Mansﬁeld P, Ajani J et al. Comprehensive geriatric assessment in patients with gastric
and gastroesophageal adenocarcinoma undergoing
gastrectomy. J Surg Oncol 2015;112:883–887.
24. McAlpine J, Hodgson E, Abramowitz S et al.
The incidence and risk factors associated with
postoperative delirium in geriatric patients
undergoing surgery for suspected gynecologic
malignancies. Gynecol Oncol 2008;109:296–302.

www.TheOncologist.com

e107
25. Choi KS, Jeong YM, Lee E et al. Association of
pre-operative medication use with post-surgery
mortality and morbidity in oncology patients receiving comprehensive geriatric assessment. Aging Clin
Exp Res 2018;30:1177–1185.
26. Westley T, Syrowatka A, Henault D et al. Patterns and predictors of emergency department
visits among older patients after breast cancer surgery: A population-based cohort study. J Geriatr
Oncol 2018;9:204–213.
27. Jeong YM, Lee E, Kim KI et al. Association of
pre-operative medication use with post-operative
delirium in surgical oncology patients receiving
comprehensive geriatric assessment. BMC Geriatr
2016;16:134.
28. de Glas NA, Kiderlen M, Bastiaannet E et al.
Postoperative complications and survival of elderly
breast cancer patients: A FOCUS study analysis.
Breast Cancer Res Treat 2013;138:561–569.
29. Samuelsson K, Egenvall M, Klarin I et al. Inappropriate drug use in elderly patients is associated
with prolonged hospital stay and increased postoperative mortality after colorectal cancer surgery: A population-based study. Colorectoral Dis
2016;18:155–162.
30. Elliot K, Tooze JA, Geller R et al. The prognostic importance of polypharmacy in older adults
treated for acute myelogenous leukemia (AML).
Leuk Res 2014;38:1184–1190.
31. Maggiore RJ, Dale W, Gross CP et al. Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing
chemotherapy: Effect on chemotherapy-related
toxicity and hospitalization during treatment. J
Am Geriatr Soc 2014;62:1505–1512.
32. Park JW, Roh JL, Lee SW et al. Effect of polypharmacy and potentially inappropriate medications on treatment and posttreatment courses in
elderly patients with head and neck cancer. J
Cancer Res Clin Oncol 2016;142:1031–1040.
33. Sasaki T, Fujita K, Sunakawa Y et al. Concomitant polypharmacy is associated with irinotecanrelated adverse drug reactions in patients with
cancer. Int J Clin Oncol 2013;18:735–742.
34. Iurlo A, Nobili A, Latagliata R et al. Imatinib
and polypharmacy in very old patients with
chronic myeloid leukemia: Effects on response
rate, toxicity and outcome. Oncotarget 2016;7:
80083–80090.

patients with cancer. Support Care Cancer 2014;
22:773–781.
39. Ting YT, Yin TX, Si P et al. Drug-related problems in elderly patients with cancer receiving
outpatient chemotherapy. J Geriatr Oncol 2015;
6:280–287.
40. Sud S, Lai P, Zhang T et al. Chemotherapy in
the oldest old: The feasibility of delivering cytotoxic therapy to patients 80 years old and older.
J Geriatr Oncol 2015;6:395–400.
41. Antonio M, Carmona-Bayonas A, Saldaña J
et al. Factors predicting adherence to a tailoreddose adjuvant treatment on the basis of geriatric
assessment in elderly people with colorectal cancer: A prospective study. Clin Colorectal Cancer
2017;17:e59–e68.
42. Turner JP, Shakib S, Singhal N et al. Prevalence and factors associated with polypharmacy
in older people with cancer. Support Care Cancer
2014;22:1727–1734.
43. van Abbema D, van Vuuren A, van den
Berkmortel F et al. Functional status decline in
older patients with breast and colorectal cancer
after cancer treatment: A prospective cohort
study. J Geriatr Oncol 2017;8:176–184.
44. Turner JP, Jamsen KM, Shakib S et al. Polypharmacy cut-points in older people with cancer:
How many medications are too many? Support
Care Cancer 2016;24:1831–1840.
45. Prithviraj GK, Koroukian S, Margevicius S et
al Patient Characteristics associated with polypharmacy and inappropriate prescribing of medications among older adults with cancer. J Geriatr
Oncol 2012;3:228–237.
46. Pamoukdjian F, Aparicio T, Zelek L et al.
Impaired mobility, depressed mood, cognitive
impairment and polypharmacy are independently associated with disability in older cancer
outpatients: The prospective Physical Frailty in
Elderly Cancer patients (PF-EC) cohort study. J
Geriatr Oncol 2017;8:190–195.
47. Williams GR, Deal AM, Nyrop KA et al. Geriatric assessment as an aide to understanding
falls in older adults with cancer. Support Care
Cancer 2015;23:2273–2280.
48. Vande Walle N, Kenis C, Heeren P et al. Fall
predictors in older cancer patients: A multicenter
prospective study. BMC Geriatr 2014;14:135.

35. Iurlo A, Ubertis A, Artuso S et al. Comorbidities and polypharmacy impact on complete
cytogenetic response in chronic myeloid leukaemia elderly patients. Eur J Intern Med 2014;25:
63–66.

49. Hamaker ME, Mitrovic M, Stauder R. The G8
screening tool detects relevant geriatric impairments and predicts survival in elderly patients
with a haematological malignancy. Ann Hematol
2014;93:1031–1040.

36. Hamaker ME, Seynaeve C, Wymenga AN et
al. Baseline comprehensive geriatric assessment is
associated with toxicity and survival in elderly
metastatic breast cancer patients receiving singleagent chemotherapy: Results from the OMEGA
study of the Dutch Breast Cancer Trialists’ Group.
Breast 2014;23:81–87.

50. Caparrotti F, O’Sullivan B, Bratman SV et al.
Exploring the impact of human papillomavirus status, comorbidity, polypharmacy, and treatment
intensity on outcome of elderly oropharyngeal
cancer patients treated with radiation therapy
with or without chemotherapy. Int J Radiat Oncol
Biol Phys 2017;98:858–867.

37. Woopen H, Richter R, Chekerov R et al. The
inﬂuence of polypharmacy on grade III/IV toxicity,
prior discontinuation of chemotherapy and
survival in recurrent ovarian cancer patients: An
individual participant data meta-analysis of the
North-Eastern German Society of Gynecological
Oncology (NOGGO) of 1,213 patients. J Clin Oncol
2015;33(suppl)5533a.

51. Falandry C, Weber B, Savoye AM et al.
Development of a geriatric vulnerability score in
elderly patients with advanced ovarian cancer
treated with ﬁrst-line carboplatin: A GINECO prospective trial. Ann Oncol 2013;24:2808–2813.

38. Kim JW, Kim YJ, Lee KW et al. The early discontinuation of palliative chemotherapy in older

52. Freyer G, Geay JF, Touzet S et al. Comprehensive geriatric assessment predicts tolerance
to chemotherapy and survival in elderly patients
with advanced ovarian carcinoma: A GINECO
study. Ann Oncol 2005;16:1795–1800.

© AlphaMed Press 2019

Polypharmacy and PIM in Older Adults with Cancer

e108
53. Nieder C, Mannsaker B, Pawinski A et al.
Polypharmacy in older patients ≥70 years receiving palliative radiotherapy. Anticancer Res 2017;
37:795–799.
54. Karuturi MS, Holmes HM, Lei X et al. Potentially inappropriate medication use in older
patients with breast and colorectal cancer. Cancer
2018;124:3000–3007.
55. Jun D, Lee W, Xing S, Calip G. Polypharmacy
and adherence to adjuvant endocrine therapy
for breast cancer. J Am Pharm Assoc 2016;56
(3):e13.
56. Kapoor J, Agrawal N, Ahmed R et al. Factors
inﬂuencing adherence to imatinib in Indian
chronic myeloid leukemia patients: A cross-sectional study. Mediterr J Hematol Infect Dis 2015;7:
e2015013.
57. Kuo SZ, Haftek M, Lai JC. Factors associated
with medication non-adherence in patients with
end-stage liver disease. Dig Dis Sci 2017;62:
543–549.
58. Nightingale G, Hajjar E, Guo K et al. A pharmacist-led medication assessment used to determine a more precise estimation of the prevalence
of complementary and alternative medication
(CAM) use among ambulatory senior adults with
cancer. J Geriatr Oncol 2015;6:411–417.
59. Parks RM, Hall L, Tang SW et al. The potential value of comprehensive geriatric assessment
in evaluating older women with primary operable breast cancer undergoing surgery or nonoperative treatment—A pilot study. J Geriatr
Oncol 2015;6:46–51.

Asian patients with cancer. J Geriatr Oncol 2016;7:
211–218.
63. Caillet P, Canoui-Poitrine F, Vouriot J et al.
Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. J Clin Oncol 2011;29:3636–
3642.
64. Lin RJ, Ma H, Guo R et al. Potentially inappropriate medication use in elderly non-Hodgkin
lymphoma patients is associated with reduced
survival and increased toxicities. Br J Haematol
2018;180:267–270.
65. Chiang LY, Liu J, Flood KL et al. Geriatric
assessment as predictors of hospital readmission
in older adults with cancer. J Geriatr Oncol 2015;
6:254–261.
66. Fastbom J, Johnell K. National indicators for
quality of drug therapy in older persons: The
Swedish experience from the ﬁrst 10 years.
Drugs Aging 2015;32:189–199.
67. Hammond T, Wilson A. Polypharmacy and
falls in the elderly: A literature review. Nurs Midwifery Stud 2013;2:171–175.
68. Todd A, Holmes HM. Recommendations to
support deprescribing medications late in life.
Ing J Clin Pharm 2015;37:678–681.
69. Forster AJ, Murff HJ, Peterson JF et al. The
incidence and severity of adverse events affecting patients after discharge from the hospital.
Ann Intern Med 2003;138:161–167.
70. Scripture CD, Figg WD. Drug interactions in
cancer therapy. Nat Rev Cancer 2006;6:546–558.

74. Fick DM, Cooper JW, Wade WE et al.
Updating the Beers criteria for potentially inappropriate medication use in older adults: Results
of a US consensus panel of experts. Arch Intern
Med 2003;163:2716–2724.
75. Gallagher P, O’Mahony D. STOPP (Screening
Tool of Older Persons’ potentially inappropriate
Prescriptions): Application to acutely ill elderly
patients and comparison with Beers’ criteria. Age
Ageing 2008;37:673–679.
76. Lund JL, Sanoff HK, Peacock Hinton S et al.
Potential medication-related problems in older
breast, colon, and lung cancer patients in the
United States. Cancer Epidemiol Biomarkers Prev
2018;27:41–49.
77. Feng X, Higa GM, Safarudin F et al. Potentially inappropriate medication use and associated healthcare utilization and costs among
older adults with colorectal, breast, and prostate
cancers. J Geriatr Oncol 2019 [Epub ahead of
print].
78. Karuturi MS, Holmes HM, Lei X et al. Potentially inappropriate medications deﬁned by
STOPP criteria in older patients with breast and
colorectal cancer. J Geriatr Oncol 2019 [Epub
ahead of print].
79. Kua CH, Mak VSL, Huey Lee SW. Health outcomes of deprescribing interventions among
older residents in nursing homes: A systematic
review and meta-analysis. J Am Med Dir Assoc
2018;20:362–372.e11.

71. McIsaac DI, Wong CA, Bryson GL et al. Association of polypharmacy with survival, complications, and healthcare resource use after elective
noncardiac surgery: A population-based cohort
study. Anesthesiology 2018;128:1140–1150.

80. Whitman AM, DeGregory KA, Morris AL
et al. A comprehensive look at polypharmacy
and medication screening tools for the older
cancer patient. The Oncologist 2016;21:
723–730.
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